Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 6, 2005, Pages 468-478

  Niemi, Mikko ^a   Backman, Janne T ^b   Kajosaari, Lauri I ^b   Leathart, Julian B ^b   Neuvonen, Mikko ^b   Daly, Ann K ^b   Eichelbaum, Michel ^b   Kivistö, Kari T ^b   Neuvonen, Pertti J ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; ORGANIC ANION TRANSPORTER; POLYPEPTIDE; REPAGLINIDE;

ADULT; ALLELE; ANION TRANSPORT; ARTICLE; CLINICAL TRIAL; FEMALE; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; CARBAMATES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENES, MDR; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ORGANIC ANION TRANSPORT POLYPEPTIDE C; P-GLYCOPROTEIN; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 20444466590     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.01.018     Document Type: Article

References (39)

1. V. Hatorp Clinical pharmacokinetics and pharmacodynamics of repaglinide Clin Pharmacokinet 41 2002 471 483
2. V. Hatorp, S. Oliver, C.A. Su Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers Int J Clin Pharmacol Ther 36 1998 636 641
3. P.N. van Heiningen, V. Hatorp, K. Kramer Nielsen, K.T. Hansen, J.J. van Lier, N.C. De Merbel Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing Eur J Clin Pharmacol 55 1999 521 525
4. T.B. Bidstrup, I. Bjørnsdottir, U.G. Sidelmann, M.S. Thomsen, K.T. Hansen CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide Br J Clin Pharmacol 56 2003 305 314
5. M. Niemi, J.B. Leathart, M. Neuvonen, J.T. Backman, A.K. Daly, P.J. Neuvonen Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide Clin Pharmacol Ther 74 2003 380 387
6. M. Niemi, P.J. Neuvonen, K.T. Kivistö The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide Clin Pharmacol Ther 70 2001 58 65
7. M. Niemi, J.T. Backman, M. Neuvonen, P.J. Neuvonen Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide potentially hazardous interaction between gemfibrozil and repaglinide Diabetologia 46 2003 347 351
8. K.T. Olkkola, J.T. Backman, P.J. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 1994 481 485
9. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara Jr, S.D. Hall The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 1998 133 143
10. E.J. Wang, K. Lew, C.N. Casciano, R.P. Clement, W.W. Johnson Interaction of common azole antifungals with P glycoprotein Antimicrob Agents Chemother 46 2002 160 165
11. H. Wakasugi, I. Yano, T. Ito, T. Hashida, T. Futami, R. Nohara Effect of clarithromycin on renal excretion of digoxin interaction with P-glycoprotein Clin Pharmacol Ther 64 1998 123 128
12. M.F. Fromm Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol Sci 25 2004 423 429
13. M. Niemi, L.I. Kajosaari, M. Neuvonen, J.T. Backman, P.J. Neuvonen The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects Br J Clin Pharmacol 57 2004 441 447
14. J.S. Wang, M. Neuvonen, X. Wen, J.T. Backman, P.J. Neuvonen Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes Drug Metab Dispos 30 2002 1352 1356
15. Y. Shitara, M. Hirano, H. Sato, Y. Sugiyama Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil J Pharmacol Exp Ther 311 2004 228 236
16. B. Hagenbuch, P.J. Meier Organic anion transporting polypeptides of the OATP/SLC21 family phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties Pflugers Arch 447 2004 653 665
17. A.K. Daly Pharmacogenetics of the major polymorphic metabolizing enzymes Fundam Clin Pharmacol 17 2003 27 41
18. W. Huang, Y.S. Lin, D.J. McConn II, J.C. Calamia, R.A. Totah, N. Isoherranen Evidence of significant contribution from CYP3A5 to hepatic drug metabolism Drug Metab Dispos 32 2004 1434 1445
19. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
20. B.P. King, J.B. Leathart, E. Mutch, F.M. Williams, A.K. Daly CYP3A5 phenotype-genotype correlations in a British population Br J Clin Pharmacol 55 2003 625 629
21. C. Marzolini, E. Paus, T. Buclin, R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
22. M. Schwab, M. Eichelbaum, M.F. Fromm Genetic polymorphisms of the human MDR1 drug transporter Annu Rev Pharmacol Toxicol 43 2003 285 307
23. R.G. Tirona, B.F. Leake, G. Merino, R.B. Kim Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European- and African-Americans J Biol Chem 276 2001 35669 35675
24. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 2003 554 565
25. J. Mwinyi, A. Johne, S. Bauer, I. Roots, T. Gerloff Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics Clin Pharmacol Ther 75 2004 415 421
26. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
27. L.I. Kajosaari, J.T. Backman, M. Neuvonen, J. Laitila, P.J. Neuvonen Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide Br J Clin Pharmacol 58 2004 390 396
28. T. Furuno, M.T. Landi, M. Ceroni, N. Caporaso, I. Bernucci, G. Nappi Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease Pharmacogenetics 12 2002 529 534
29. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 2002 584 594
30. Y. Shitara, T. Itoh, H. Sato, A.P. Li, Y. Sugiyama Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A J Pharmacol Exp Ther 304 2003 610 616
31. M. Hedman, P.J. Neuvonen, M. Neuvonen, C. Holmberg, M. Antikainen Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression Clin Pharmacol Ther 75 2004 101 109
32. T. Hatanaka Clinical pharmacokinetics of pravastatin mechanisms of pharmacokinetic events Clin Pharmacokinet 39 2000 397 412
33. S.G. Simonson, A. Raza, P.D. Martin, P.D. Mitchell, J.A. Jarcho, C.D. Brown Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin Pharmacol Ther 76 2004 167 177
34. D. Dai, D.C. Zeldin, J.A. Blaisdell, B. Chanas, S.J. Coulter, B.I. Ghanayem Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 2001 597 607
35. A. Soyama, Y. Saito, N. Hanioka, N. Murayama, O. Nakajima, N. Katori Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism Biol Pharm Bull 24 2001 1427 1430
36. N. Bahadur, J.B. Leathart, E. Mutch, D. Steimel-Crespi, S.A. Dunn, R. Gilissen CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 2002 1579 1589
37. E. Garcia-Martin, C. Martinez, B. Tabares, J. Frias, J.A. Agundez Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms Clin Pharmacol Ther 76 2004 119 127
38. E. Schaeffeler, M. Eichelbaum, U. Brinkmann, A. Penger, S. Asante-Poku, U.M. Zanger Frequency of C3435T polymorphism of MDR1 gene in African people Lancet 358 2001 383 384
39. K. Tang, L.P. Wong, E.J. Lee, S.S. Chong, C.G. Lee Genomic evidence for recent positive selection at the human MDR1 gene locus Hum Mol Genet 13 2004 783 797